Medicines planning
47 results
Applied filters
The licence and supporting evidence for denosumab 60mg biosimilars
24 April 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for omalizumab biosimilar
20 April 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. Review its indications, evidence, and main differences.
Preparing to use omalizumab biosimilar
20 April 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. We offer general information and implementation advice.
New Medicines News
9 April 2026New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes.
The licence and supporting evidence for tocilizumab biosimilar
6 March 2026Two licensed tocilizumab biosimilars are available: Tyenne and Avtozma. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use tocilizumab biosimilar
6 March 2026Two tocilizumab biosimilars are now available. We offer general information and implementation advice.
Exagamglogene autotemcel (Casgevy®)
13 February 2026This document highlights key areas where Chief Pharmacists should focus pharmaceutical expertise prior to implementation of exagamglogene autotemcel.
Marketed CAR-T therapy
13 February 2026This document outlines key areas where Chief Pharmacists should focus pharmaceutical expertise prior to an organisation implementing CAR-T therapy.
Costing clinical trials of ATIMPs using the NIHR iCT
11 February 2026Guidance to support and promote consistent pharmacy costing for commercial clinical trials involving ATIMPs.
The licence and supporting evidence for aflibercept biosimilars
4 February 2026Aflibercept 2mg biosimilars are available for NHS use. Learn about supporting evidence and differences.